Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM.
Gisela Z, Carla P, Josefina B, Tomas I, Lucia B, Pappolla A, Miguez J, Patrucco L, Cristiano E, Norma D, Verónica T, Carlos V, Leila C, Alonso R, Garcea O, Silva B, Celica Y, Marrodan M, Gaitán MI, Correale J, Marcos B, Luciana L, Anibal C, Emanuel S, Eduardo K, Judith S, Dario T, Javier H, Pedro N, Felisa L, Pablo LA, Susana L, Patricio B, Raul P, Adriana C, Alejandra M, María Eugenia B, Contentti Edgar C, Amelia AP, Carolina M, Mariano C, Luciano R, Matias K, Eduardo K, María Celeste C, Maria Laura M, Santiago T, Mariela C, Fatima PC, Andres B, Geraldine L, Alonso Serena M, Juan Ignacio R, Marcos S; RELEVAREM Study Group.. Gisela Z, et al. Among authors: pablo la. Neurol Res. 2023 Feb;45(2):112-117. doi: 10.1080/01616412.2022.2124792. Epub 2022 Oct 2. Neurol Res. 2023. PMID: 36184106
Correction to: Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM).
Ricardo A, Cecilia Q, Bárbara E, Leila C, Berenice S, Cecilia P, Ignacio RJ, Pappolla A, Miguez J, Patrucco L, Cristiano E, Carlos V, Gabriel V, Emanuel S, Andres B, Norma D, Verónica T, Gisela Z, Dario T, Laura SM, Geraldine L, Laura MM, Edgar CC, Pablo L, Judith S, Pablo D, Javier H, Amelia AP, Adriana C, Eugenia BM, Luciana L, Nora FL, Orlando G; RelevarEM investigators. Ricardo A, et al. Neurol Sci. 2020 Nov;41(11):3369-3371. doi: 10.1007/s10072-020-04709-7. Neurol Sci. 2020. PMID: 32918634
Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies.
Alonso R, Casas M, Lazaro L, Fernandez Liguori N, Pita C, Cohen L, Rojas JI, Pappolla A, Patrucco L, Cristiano E, Burgos M, Vrech C, Piedrabuena R, Pablo L, Deri N, Luetic G, Miguez J, Cabrera M, Martinez A, Zanga G, Tkachuk V, Tizio S, Carnero Contentti E, Knorre E, Leguizamon F, Mainella C, Nofal P, Liwacki S, Hryb J, Menichini M, Pestchanker C, Alonso M, Garcea O, Silva B. Alonso R, et al. Mult Scler J Exp Transl Clin. 2023 Feb 22;9(1):20552173231154712. doi: 10.1177/20552173231154712. eCollection 2023 Jan-Mar. Mult Scler J Exp Transl Clin. 2023. PMID: 36846108 Free PMC article.
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina.
Alonso R, Casas M, Lazaro L, Liguori NF, Pita C, Cohen L, Rojas JI, Pappolla A, Patrucco L, Cristiano E, Burgos M, Vrech C, Piedrabuena R, Pablo L, Deri N, Luetic G, Miguez J, Cabrera M, Martinez A, Zanga G, Tkachuk V, Tizio S, Carnero Contentti E, Knorre E, Leguizamon F, Mainella C, Nofal P, Liwacki S, Hryb J, Menichini M, Pestchanker C, Garcea O, Silva B. Alonso R, et al. Mult Scler Relat Disord. 2023 Nov;79:104935. doi: 10.1016/j.msard.2023.104935. Epub 2023 Aug 9. Mult Scler Relat Disord. 2023. PMID: 37634468
12 results